Lilly strikes Ascidian deal worth up to $1.9B for RNA editing in kidney diseases

Summary

Eli Lilly has entered into a licensing deal with Ascidian Therapeutics valued at up to $1.9 billion for RNA editing technology targeting kidney diseases. Ascidian recently presented initial clinical data supporting the safety of this gene-fixing approach in humans.